文献速递临床试验与 GCP真实世界研究与卫生经济

伴或不伴皮质类固醇的高容量注射与假注射治疗中段跟腱病的疗效与成本效果:随机对照试验

Efficacy and cost effectiveness of high volume injections with and without corticosteroid compared with sham for midportion Achilles tendinopathy (Inject trial): randomised controlled trial.
PubMed 文献 · BMJ · 2026-10-28

这项单中心、参与者和评估者盲法的三臂随机对照试验纳入192例中段跟腱病成人,比较假注射、无皮质类固醇高容量注射和含皮质类固醇高容量注射。52周时VISA-A评分未见组间明确差异,含皮质类固醇注射虽有短期获益但26周时劣于无皮质类固醇注射,临床数据不支持常规使用含皮质类固醇高容量注射。

要点

  • 52周时高容量注射(伴或不伴皮质类固醇)与假注射在疼痛和功能障碍上无明确差异。
  • 含皮质类固醇高容量注射6周时优于假注射,但26周时劣于无皮质类固醇高容量注射。
  • 含皮质类固醇高容量注射成本低于假注射且效果相似,但长期临床结局更差。

核心结论

  • 52周时高容量注射伴或不伴皮质类固醇均未较假注射改善中段跟腱病患者的疼痛或功能障碍。
  • 含皮质类固醇高容量注射显示短期临床获益和一年内潜在医疗成本降低,但与更差的长期临床结局相关。
  • 临床数据不支持常规使用含皮质类固醇的高容量注射治疗中段跟腱病。

研究设计与样本

  • 单中心、参与者和评估者盲法、三臂随机对照试验(Inject试验)。
  • 2019年12月5日至2022年7月24日从社区纳入192例18岁及以上确诊中段跟腱病的成人,按1:1:1随机分配至假注射组(n=64)、无皮质类固醇高容量注射组(n=63)或含皮质类固醇高容量注射组(n=65)。
  • 所有参与者接受相同的运动方案、教育和活动调整建议。

主要发现

  • 12个月时获得181/192例(94%)参与者的VISA-A数据。
  • 12个月时假注射与含皮质类固醇高容量注射比较的VISA-A差异为-3.5(98.33%CI -12.0至5.0),与无皮质类固醇高容量注射比较为4.0(-4.2至12.3),两种注射之间为-7.5(-15.3至0.3)。
  • 6周时含皮质类固醇高容量注射优于假注射,VISA-A差异为9.2(1.5至16.9);26周时含皮质类固醇高容量注射劣于无皮质类固醇高容量注射,差异为-8.6(-16.4至-0.7)。
  • 未记录到与试验相关的严重不良事件。

关键数值与推荐

  • 主要临床结局为经验证的VISA-A评估的疼痛和功能障碍,主要终点为52周。
  • 经济学结局为从社会角度计算的每质量调整生命年成本。
  • 假注射成分为2-3 mL 0.5%盐酸布比卡因;含皮质类固醇高容量注射为50 mL生理盐水和0.5%布比卡因,前10 mL中含25 mg氢化可的松;无皮质类固醇高容量注射为相同溶液但不含氢化可的松。

临床怎么用

  • 中段跟腱病患者不应常规接受含皮质类固醇的高容量注射治疗。
  • 含皮质类固醇高容量注射的短期获益需权衡其长期临床结局更差的风险。
  • 所有组均接受运动方案、教育和活动调整建议,注射本身未显示额外长期获益。

局限性

  • 单中心设计可能限制结果的外推性。
  • 12个月时VISA-A随访率为94%,存在少量失访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test the efficacy and cost effectiveness of high volume injections with and without corticosteroid versus sham injection for midportion Achilles tendinopathy. DESIGN: Single centred, participant and assessor masked, three arm randomised controlled trial (Inject trial). SETTING: Community. PARTICIPANTS: From 5 December 2019 and 24 July 2022, 192 adults (18 years or older) diagnosed with midportion Achilles tendinopathy were randomly assigned (1:1:1) to sham (n=64), high volume injection without corticosteroid (n=63), or high volume injection with corticosteroid (n=65). INTERVENTIONS: Participants were allocated to sham injection (2-3 mL 0.5% bupivacaine hydrochloride), high volume injection with corticosteroid (50 mL saline and 0.5% bupivacaine with 25 mg hydrocortisone in the first 10 mL), or high volume injection with no corticosteroid (same solution but without hydrocortisone). They received the same exercise programme, education, and activity modification advice. MAIN OUTCOME MEASURES: The primary clinical outcome was pain and disability using the validated VISA-A and the primary endpoint was at 52 weeks. The economic outcome was cost per quality-adjusted life-years from a societal perspective. RESULTS: VISA-A data were obtained from 181 (94%) of 192 participants at 12 months. No clear differences were noted between sham and high volume injection either with (-3.5 (98.33% confidence interval -12.0 to 5.0)) or without corticosteroid (4.0 (-4.2 to 12.3)), and between the two injections (-7.5 (-15.3 to 0.3)), at 12 months. The point estimate was closest to the target difference for the comparison between injections and favoured the arm without steroid. The only differences observed on VISA-A at intermediate time points were a benefit for high volume with corticosteroid versus sham at six weeks (9.2 (1.5 to 16.9)) but worse outcomes for high volume injection with corticosteroid versus high volume injection with no corticosteroid at 26 weeks (-8.6 (-16.4 to -0.7)). The health economic analysis found high volume injection with corticosteroid to be less costly than the sham with similar effectiveness based on quality-adjusted life-years (>0.90 probability of being cost effective at $AUD50 000 and $100 000 willingness-to-pay thresholds). No serious trial related adverse events were recorded. CONCLUSION: High volume injections with or without corticosteroids did not improve pain or disability compared with sham at 12 months. Although high volume injections with corticosteroid showed short term clinical benefit and potential reduction in healthcare costs over a year, they were associated with worse longer term clinical outcomes. The clinical data do not support routine use for high volume injections with corticosteroid for midportion Achilles tendinopathy. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12619001455156.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Malliaras P, Connell D, Boesen AP, et al. Efficacy and cost effectiveness of high volume injections with and without corticosteroid compared with sham for midportion Achilles tendinopathy (Inject trial): randomised controlled trial. BMJ. 2026. PMID: 42951276. doi:10.1136/bmj-2026-100807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。